ArticleClinical & experimental metastasis2024

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model.

Negar Pourjamal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.